.jpg)
This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies.
Human medicines European public assessment report (EPAR): Apretude, cabotegravir...
Human medicines European public assessment report (EPAR): Thyrogen, thyrotropin ...
Clinical Trial Information System (CTIS) - Sponsor handbook
Radiance Biopharma is heating up the ROR1 race. The U.S. biotech is paying China...
Merck & Co. has penned a $300 million biobucks-per-product deal with cancer biot...
Supernus Pharmaceuticals may have had a potential path forward for its depressio...
While the FDA’s diversity guidance for clinical trials has been temporarily rest...
Human medicines European public assessment report (EPAR): Nemluvio, nemolizumab,...
Human medicines European public assessment report (EPAR): Siiltibcy, Mycobacteri...
The tuberculosis outbreak in the Kansas City area is not, in fact, the largest i...
RFK Jr. wants to tackle the GRAS exemption, which allows companies to put chemic...
If policymakers fail to act swiftly to restore medical research funding, then it...
Human medicines European public assessment report (EPAR): Neupro, rotigotine, Da...
Human medicines European public assessment report (EPAR): Blenrep, belantamab ma...
Orphan designation: Humanised monoclonal antibody targeting B-cell maturation an...
Human medicines European public assessment report (EPAR): Galvus, vildagliptin, ...
Human medicines European public assessment report (EPAR): Erbitux, cetuximab, Da...
While the FDA’s diversity guidance for clinical trials has been temporarily rest...
Local pharma groups have taken over a lucrative niche market
According to a fact sheet provided by the White House, Trump's IVF order will fo...